College of Public Health: Faculty Publications
About the Collection
Collection preserves publications by current and former faculty and staff.
Need Help?
Have a question about GS Commons? Need additional description, text alternatives, or captions for GS Commons resources? Contact us or request accessible formats (opens in new tab).
from 2020
Hypertension and Diabetes Synergistically Strengthen the Association with Cataracts among Chinese: Implications for Clinical Practice and Public Health Policy, Jin-Jin Li, Mo-Dong Li, Jie Li, Xiao Yang, Dan Xia, Yu Li, Wei Wang, Fei Yan, and Jian Zhang
Statistical Considerations for Clinical Trials During COVID-19: An Adaptive Hybrid Design for Clinical Development in Rare Diseases, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials in Patients with COVID-19 High Risks, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials with Chronic Conditions, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Background, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part II), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Impacts on Permuted Block Randomization and Mitigations, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Integrated Analysis of Efficacy (IAE) with Adaptive Estimands, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Interim Analysis with Adaptive Estimands Based, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part I), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part II), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part III), Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation, Qing Liu and Karl E. Peace
Statistical Considerations for Clinical Trials During COVID-19: Unplanned Changes in Estimands with Two-Stage Adaptive Designs, Qing Liu and Karl E. Peace
Cluster analysis of urinary tobacco biomarkers among U.S. adults: Population Assessment of Tobacco and Health (PATH) biomarker study (2013–2014), Ban Majeed, Daniel F. Linder, Thomas Eissenberg, Yelena Tarasenko, Danielle Smith, and David Ashley
